血红蛋白变异体对HbA1c定量检测的干扰
HbA1c反映8-12周平均血糖控制,但血红蛋白遗传变异体可干扰离子交换层析、毛细管电泳、免疫分析和硼酸亲和层析等HbA1c定量方法。质谱法测量α和β珠蛋白链的总糖化,与离子交换法相关性好,且不受血红蛋白遗传变异体影响,可能是糖尿病更好的分析选择。
要点
- 血红蛋白遗传变异体可干扰多种常规HbA1c定量方法。
- 质谱法测总糖化不受血红蛋白变异体影响,与离子交换法相关好。
- 质谱法可能是糖尿病HbA1c监测的更好分析选择。
核心结论
- 血红蛋白遗传变异体可干扰离子交换层析、毛细管电泳、免疫分析和硼酸亲和层析法对HbA1c的定量。
- 质谱法测量α和β珠蛋白链的总糖化,与离子交换法相关性好,且不受血红蛋白遗传变异体影响,可能是糖尿病更好的分析选择。
主要发现
- HbA1c反映8-12周长期血糖控制,空腹血糖是短期指标。
- 血红蛋白遗传变异体可干扰离子交换层析、毛细管电泳、免疫分析和硼酸亲和层析法对HbA1c的定量。
- 质谱法测量α和β珠蛋白链的总糖化,与离子交换法相关性好,且不受血红蛋白遗传变异体影响。
临床怎么用
- 对于存在血红蛋白遗传变异体的糖尿病患者,质谱法可能是更可靠的HbA1c分析选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fasting blood glucose and glycated hemoglobin (HbA1c) are routine biomarkers to screen and monitor diabetes mellitus. HbA1c results from glycation at the N-terminus of the β globin chain of tetrameric human hemoglobin. Fasting blood glucose level varies with the nature and amount of food intake, physical exercise, etc., and, accordingly, is a short-term measure of glucose control. In contrast, HbA1c provides an average measure of glucose control for the long-term (8-12 weeks). Unfortunately, genetic variants of hemoglobin may interfere with HbA1c quantification using ion exchange chromatography, capillary electrophoresis, immunoassay and boronate affinity chromatography. Mass spectrometry, however, measures total glycation of hemoglobin across both α and β globin chains and correlates well with the ion exchange based method. Additionally, mass spectrometry based quantification is not impacted by the presence of genetic variants of hemoglobin and thus might be a better analytical choice for diabetes mellitus.
引用
- Yadav N, Kumar Mandal A. Interference of hemoglobin variants in HbA1c quantification. Clin Chim Acta. 2022. PMID: 36476843. doi:10.1016/j.cca.2022.11.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。